These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 32269460)
21. Oncologic outcomes at 10 years following robotic radical prostatectomy. Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687 [TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related]
23. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL; J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734 [TBL] [Abstract][Full Text] [Related]
24. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance. Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730 [TBL] [Abstract][Full Text] [Related]
25. Increased body mass index as a risk factor in localized prostate cancer treated by radical prostatectomy. Goris Gbenou MC; Peltier A; Schulman CC; Velthoven Rv Urol Oncol; 2016 Jun; 34(6):254.e1-6. PubMed ID: 26822075 [TBL] [Abstract][Full Text] [Related]
26. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
27. Effect of BMI on primary treatment of prostate cancer. Davies BJ; Walsh TJ; Ross PL; Knight SJ; Sadetsky N; Carroll PR; Kane CJ Urology; 2008 Aug; 72(2):406-11. PubMed ID: 18267336 [TBL] [Abstract][Full Text] [Related]
28. Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysis. Brandes A; Koerber F; Schwarzkopf L; Hunger M; Rogowski WH; Waidelich R BMC Health Serv Res; 2016 Nov; 16(1):664. PubMed ID: 27863486 [TBL] [Abstract][Full Text] [Related]
29. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. Wilt TJ; Brawer MK J Urol; 1994 Nov; 152(5 Pt 2):1910-4. PubMed ID: 7523736 [TBL] [Abstract][Full Text] [Related]
30. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485 [TBL] [Abstract][Full Text] [Related]
31. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Siddiqui SA; Inman BA; Sengupta S; Slezak JM; Bergstralh EJ; Leibovich BC; Zincke H; Blute ML Cancer; 2006 Aug; 107(3):521-9. PubMed ID: 16773619 [TBL] [Abstract][Full Text] [Related]
32. Patient comorbidity is associated with conservative treatment of localized prostate cancer. Jespersen CG; Nørgaard M; Jacobsen JB; Borre M Scand J Urol; 2015; 49(5):366-70. PubMed ID: 25903072 [TBL] [Abstract][Full Text] [Related]
33. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
34. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Pettersson A; Robinson D; Garmo H; Holmberg L; Stattin P Ann Oncol; 2018 Feb; 29(2):377-385. PubMed ID: 29161337 [TBL] [Abstract][Full Text] [Related]
35. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
36. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients. Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626 [TBL] [Abstract][Full Text] [Related]
37. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer]. Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328 [TBL] [Abstract][Full Text] [Related]
38. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194 [TBL] [Abstract][Full Text] [Related]
39. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men. Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420 [TBL] [Abstract][Full Text] [Related]
40. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era. Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]